Analytical Data
-
Gene name
USP46
- Application
-
Alternative Names
USP46；Ubiquitin carboxyl-terminal hydrolase 46
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62068
-
Expression Region
1-366aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMTVRNIA SICNMGTNAS ALEKDIGPEQ FPINEHYFGL VNFGNTCYCN SVLQALYFCR PFRENVLAYK AQQKKKENLL TCLADLFHSI ATQKKKVGVI PPKKFISRLR KENDLFDNYM QQDAHEFLNY LLNTIADILQ EEKKQEKQNG KLKNGNMNEP AENNKPELTW VHEIFQGTLT NETRCLNCET VSSKDEDFLD LSVDVEQNTS ITHCLRDFSN TETLCSEQKY YCETCCSKQE AQKRMRVKKL PMILALHLKR FKYMEQLHRY TKLSYRVVFP LELRLFNTSS DAVNLDRMYD LVAVVVHCGS GPNRGHYITI VKSHGFWLLF DDDIVEKIDA QAIEEFYGLT SDISKNSESG YILFYQSRE
-
Molecular Weight
45 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
USP46 (Ubiquitin-specific protease 46) is a member of the deubiquitinating enzyme family, which plays a critical role in the regulation of protein turnover and signaling pathways by removing ubiquitin moieties from proteins. Dysregulation of ubiquitination processes is associated with various diseases, including cancer and neurodegenerative disorders, making USP46 a potential therapeutic target. Previous studies have highlighted its involvement in neuronal development and stress responses, implicating it in synaptic plasticity and neuroprotection. Research has emphasized the enzyme's substrate specificity, revealing its role in modulating key signaling pathways such as the NF-κB and mTOR pathways. Furthermore, the structural characterization of USP46 offers insights into its catalytic mechanism and interaction with ubiquitinated proteins, paving the way for the development of small-molecule inhibitors. Understanding the precise functions and mechanisms of USP46 may provide valuable information for designing innovative treatment strategies that harness the ubiquitin-proteasome system, ultimately contributing to advancements in precision medicine for diseases linked to protein misfolding and degradation. This ongoing research underscores the potential of USP46 as a novel target in the context of therapeutic interventions in neurodegenerative diseases and cancer, making it a significant focus for future studies.
